文献速递角膜与眼表疾病

地塞米松泪道栓插入剂治疗过敏性结膜炎的3期随机研究

Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis.
PubMed 文献 · Am J Ophthalmol · 2021-03-25

这项多中心、随机、双盲、安慰剂对照的3期试验评估地塞米松泪道插入剂治疗过敏性结膜炎的疗效与安全性。受试者双眼按1:1随机接受地塞米松或安慰剂插入剂,采用改良结膜过敏原激发(CAC)模型评估。结果显示地塞米松插入剂在第1周CAC后多个时间点显著降低眼痒评分,结膜充血在20分钟时显著降低,无严重不良事件。

要点

  • 地塞米松插入剂在第1周CAC后3、5、7分钟眼痒评分均显著低于安慰剂(P<.001)。
  • 结膜充血仅在CAC后20分钟显著降低(P<.05),7和15分钟未达显著。
  • 无严重不良事件,1例受试者双眼眼压升高。

核心结论

  • 单次医生给药的地塞米松泪道插入剂可在过敏性结膜炎受试者中缓解眼痒长达4周,并保持有利的安全性特征。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照的3期临床试验;过敏性结膜炎受试者按1:1随机双眼接受地塞米松插入剂或安慰剂插入剂,采用改良结膜过敏原激发(CAC)模型评估。

主要发现

  • 第1周CAC后第8天,地塞米松插入剂在3、5、7分钟的眼痒平均评分均显著低于安慰剂(P<.001),差值分别为0.86、0.98、0.96单位。
  • 结膜充血评分在CAC后20分钟显著低于安慰剂(P<.05),但在7和15分钟未达显著(P≥.05)。
  • 在其余33个时间点中,分别有31个时间点的眼痒和29个时间点的结膜充血显著更轻(P<.05)。
  • 无严重不良事件;1例受试者出现双眼眼压升高。

关键数值与推荐

  • 主要疗效终点为第1周CAC后第8天评估的眼痒(CAC后3、5、7分钟)和结膜充血(CAC后7、15、20分钟)。
  • 眼痒评分在所有主要时间点均显著 favoring 地塞米松插入剂(P<.001)。
  • 结膜充血仅在CAC后20分钟显著 favoring 地塞米松插入剂(P<.05)。

临床怎么用

  • 对于过敏性结膜炎患者,可考虑单次医生给予地塞米松泪道插入剂以缓解眼痒长达4周。
  • 使用期间需关注眼压变化,因报道1例受试者出现双眼眼压升高。

局限性

  • 原文未报告样本量、具体置信区间及长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate the efficacy and safety of a dexamethasone intracanalicular ocular insert for the treatment of allergic conjunctivitis. DESIGN: Multicenter, randomized, double-masked, placebo-controlled, Phase 3 clinical trial. METHODS: Subjects with allergic conjunctivitis were randomized 1:1 to receive a dexamethasone insert or a placebo insert in both eyes and were evaluated using a modified version of the conjunctival allergen challenge (CAC) model. After inserts were placed in office, a series of 4 closely spaced post-insertion CACs were conducted at weeks 1, 2, and 4 across approximately 30 days. Primary efficacy endpoints, assessed at week-1 CAC-day 8, were reported by subjects of ocular itching at 3, 5, and 7 minutes post CAC and investigator-evaluated conjunctival redness at 7, 15, and 20 minutes post CAC. RESULTS: For the primary endpoints, dexamethasone inserts showed statistically significantly lower mean ocular itching scores than placebo at all time points (P <.001), with differences favoring dexamethasone inserts over placebo (0.86, 0.98, and 0.96 units at 3, 5, and 7 minutes, respectively) and statistically significantly lower conjunctival redness scores at 20 minutes (P <.05) but not at 7 or 15 minutes (P ≥.05). Results also showed statistically significantly less itching and conjunctival redness at 31 and 29 of 33 other time points, respectively (P <.05). There were no serious adverse events; 1 subject had elevated intraocular pressure in both eyes. CONCLUSIONS: Data presented in this study demonstrate the potential for a single, physician-administered dexamethasone intracanalicular insert to provide relief of ocular itching for up to 4 weeks in subjects with allergic conjunctivitis, while maintaining a favorable safety profile.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. McLaurin EB, Evans D, Repke CS, et al. Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. Am J Ophthalmol. 2021. PMID: 33773984. doi:10.1016/j.ajo.2021.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。